Cargando…

Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment

Management of gastrointestinal stromal tumors (GISTs) has been revolutionized by the identification of activating mutations in KIT and PDGFRA and clinical application of RTK inhibitors in advanced disease. Stratification of GISTs into molecularly defined subsets provides insight into clinical behavi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Shuai, Sharipova, Dinara, Kozinova, Marya, Klug, Lilli, D’Souza, Jimson, Belinsky, Martin G., Johnson, Katherine J., Einarson, Margret B., Devarajan, Karthik, Zhou, Yan, Litwin, Samuel, Heinrich, Michael C., DeMatteo, Ronald, von Mehren, Margaret, Duncan, James S., Rink, Lori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934848/ https://www.ncbi.nlm.nih.gov/pubmed/33320833 http://dx.doi.org/10.1172/jci.insight.143474

Ejemplares similares

Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor
por: Kozinova, Marya, et al.
Publicado: (2021)

Succinate Dehydrogenase Deficiency in Pediatric and Adult Gastrointestinal Stromal Tumors
por: Belinsky, Martin G., et al.
Publicado: (2013)

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy
por: George, Suzanne, et al.
Publicado: (2021)

Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021)

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data
por: von Mehren, Margaret, et al.
Publicado: (2021)

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
por: Kang, Yoon-Koo, et al.
Publicado: (2021)

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
por: Joseph, Cissimol P., et al.
Publicado: (2021)

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
por: Jones, Robin L., et al.
Publicado: (2021)

The Role of Avapritinib for the Treatment of Systemic Mastocytosis
por: Sumbly, Vikram, et al.
Publicado: (2021)

Photosensitivity From Avapritinib: Pharamacovigilance Analysis
por: Venkatakrishnan, Ajit, et al.
Publicado: (2022)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
por: Belinsky, Martin G., et al.
Publicado: (2017)

Avapritinib-induced photo-aggravated cutaneous reaction
por: Dadrass, Farinoosh, et al.
Publicado: (2022)

The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation
por: Trullas-Jimeno, A., et al.
Publicado: (2021)

Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia
por: Sandow, Lyndsey, et al.
Publicado: (2023)

Successful treatment with avapritinib in patient with mucosal metastatic melanoma
por: Cocorocchio, Emilia, et al.
Publicado: (2020)

Palpable purpuric eruption mimicking vasculitis following avapritinib
por: Mohammed, Taha Osman, et al.
Publicado: (2022)

Avapritinib in advanced gastrointestinal stromal tumor: case series and review of the literature from a tertiary care center in India
por: Verma, Saurav, et al.
Publicado: (2021)

Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case
por: Belinsky, Martin G., et al.
Publicado: (2015)

Abrupt onset of severe parkinsonism in a patient with metastatic gastrointestinal stromal tumor receiving treatment with avapritinib: A case report()
por: Drom, Claire, et al.
Publicado: (2022)

Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells
por: Rødland, Gro Elise, et al.
Publicado: (2021)

Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis
por: Cavazos, Karla, et al.
Publicado: (2022)

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study
por: Li, Jian, et al.
Publicado: (2022)

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
por: DeAngelo, Daniel J., et al.
Publicado: (2021)

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study
por: Chun, Yun Shin, et al.
Publicado: (2014)

Air raids and the 'Wee' Hospital.
por: Logan, C. J. H.
Publicado: (2003)

Expressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis
por: Eom, Minseob, et al.
Publicado: (2012)

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
por: Gotlib, Jason, et al.
Publicado: (2021)

Combination of Type I and II tyrosine kinase inhibitors—avapritinib and sunitinib—in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report
por: Guo, Xiaodan, et al.
Publicado: (2022)

A Wee Lesson in Science Communication
por: King, Emma
Publicado: (2004)

Pedicures, wees alert op ‘coronatenen’
por: van Putten, Margreet
Publicado: (2020)

WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
por: Mannelli, Francesco, et al.
Publicado: (2023)

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
por: Bauer, Sebastian, et al.
Publicado: (2021)

Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan
por: Proudman, David, et al.
Publicado: (2020)

Recent Advances in the Synthesis and Applications of m-Aryloxy Phenols
por: Amankulova, Dinara, et al.
Publicado: (2023)

Cdc25 and Wee1: analogous opposites?
por: Perry, Jennifer A, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ldqjm3t7aaql7co3ru7k97csdj